Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2019

View Archived Issues

AMP analogues with reduced toxicity

For whom the pain bell Tolls

Immune cell stress response may play role in chronic pain

Phase III portion of the LUME-Meso study does not meet primary endpoint

CCL5 as novel biomarker associated with poor prognosis in locally advanced pancreatic cancer

AC Immune initiates phase I study of ACI-3024

Adaptimmune starts SURPASS study with its next-generation SPEAR T cells targeting MAGE-A4

Phase I study of Novo Nordisk's NNC-0247-0829 begins

Phase I plans for NTRX-07, a highly selective and potent CB2 receptor agonist

Minimal radiation exposure to staff seen with Iomab-B in phase III SIERRA trial

Phase IIa data for NA-831 in patients with MCI and mild and moderate Alzheimer's disease presented

Bionomics divulges SCN9A blockers for pain

Medshine Discovery presents new compounds for tuberculosis

Sunshine Lake Pharma identifies AOC3 inhibitors

Adlai Nortye describes IDO1 inhibitors

New CD73 inhibitors identified by Abbisko Therapeutics

CTI amends pacritinib study protocol following end of phase IIa meeting with FDA

Pharmazz cleared in India to initiate phase III study of PMZ-1620 for acute ischemic stroke

Transgene cleared to begin phase I/IIa study of TG-6002 given by intrahepatic artery infusion

Spring Bank enters HBV research agreement with NIAID

Midatech reports data from first-in-human study of MTX-102 in type 1 diabetes

Imugene to acquire Vaxinia and license to oncolytic virus CF-33

NDX-1017 safety, pharmacokinetics and pharmacodynamics in healthy subjects reported

TRAF3 conditional knockout model points to TRAF3 degradation as a target for preventing osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...